CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan spoke to Proactive, addressing negative claims made by healthcare publication STAT on its coronavirus study. Pourhassan says the company has released what he says are positive results from its coronavirus treatment clinical study, and explains why he thinks healthcare publication STAT has got it all wrong.
CytoDyn addresses negative claims made by healthcare publication STAT on its coronavirus study
Quick facts: CytoDyn Inc.
Price: 2.28 USD
Market Cap: $1.3 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE